EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Oral Acarbose Inhibits Baseline Salivary Amylase and Blunts Early Postprandial Glycemia: Randomized Cross-Over Study

Airi Sekine, Kei Nakajima

JMIR Formative Research · 2026-11-06 · 10 · e98441-e98441

DOI: 10.2196/98441 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract This study investigated whether salivary α-amylase (SAA) inhibition by acarbose affects postprandial blood glucose (BG) in healthy individuals. This single-blinded, placebo-controlled, randomized cross-over trial included 4 conditions: trial 1 (T1), placebo (oligosaccharide); trial 2 (T2), swallowing 50 mg of acarbose; and trials 3 and 4 (T3 and T4), simultaneous intake of starch (150 g of rice) with 50 mg or 100 mg of acarbose, respectively. Fifteen young, healthy women were enrolled. Peak ΔBG occurred at 30 min in both T1 and T2 and at 60 min in T3. ΔBG at 30 min was significantly lower in T3 and T4 than in T2 (both P

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →